Cholesterol Disorders

 

The Practical Cardiology™ Cholesterol Disorders clinical resource center offers the latest information from the field of lipidology. With hypercholesterolemia and hyperlipidemia representing a crucial aspect of risk management, this page will be a hub for information related to the latest in cholesterol management and dyslipidemia, including articles, videos, and podcasts.

Most Stroke Patients Have Undiagnosed Major Risk Factors

June 28, 2022

An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.

Statins Could Slow Progression of Arterial Stiffness in High-Risk Patients

June 20, 2022

A retrospective analysis comparing statin users and nonusers details the significant declines in arterial stiffness progression among patients of high atherosclerotic risk based on statin use and adherence in a cohort of more than 5000 patients.

Hypertriglyceridemia Increases Recurrent Stroke Risk, Despite Statin Use and Well-Controlled LDL-C

March 17, 2022

An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.

Analysis Suggests Statin Intolerance is Overdiagnosed

February 21, 2022

A meta-analysis of data from more than 4 million patients suggests the prevalence of statin therapy may be overdiagnosed and provides insight into risk factors associated with increased risk of intolerance.

FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH

December 22, 2021

Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.

Statin Discontinuation Associated with Excess MACE Events in Older Patients

December 13, 2021

Data from an analysis of 67k older Danes suggests statin discontinuation corresponded with 1 excess event per 112 persons per year in a primary prevention cohort and 1 excess event per 77 persons per year in a secondary prevention cohort.